{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:51:48Z","timestamp":1789757508053,"version":"4.0.1"},"reference-count":175,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CAR"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Parkinson's disease (PD) is a multifaceted neurodegenerative condition marked by the\nprogressive loss of dopaminergic neurons, leading to impairments in movement and cognition.\nThis study offers an in-depth examination of the pathophysiological pathways associated with PD,\nemphasising the roles of oxidative stress, mitochondrial dysfunction, and neuroinflammation. The\nstudy examines the interaction between genetic and environmental factors in the development of\nPD, highlighting the significance of oxidative stress, mitochondrial dysfunction, and excitotoxicity\nin the degeneration of dopaminergic neurons. It also looks into the impact of neuroinflammation\nand microglial activation on the causes of PD. Despite considerable progress in research,\nthere remains a lack of effective treatments that can modify the course of the disease, highlighting\nthe pressing need for new therapeutic approaches that address mitochondrial malfunction, oxidative\nstress, and neuroinflammation. This study assesses the neuroprotective efficacy of various substances,\nnotably natural agents like resveratrol, curcumin, ginsenoside, and melatonin, for managing\nPD. Although these natural chemicals show promise, further robust clinical trials are needed\nto confirm their effectiveness and safety, as well as to investigate their potential incorporation into\nconventional PD treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115672050368080250529075006","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T07:35:10Z","timestamp":1762846510000},"page":"634-660","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neuroprotective Agents: Implications for Parkinson's Disease Treatment"],"prefix":"10.2174","volume":"22","author":[{"given":"Khaled Ramadan","family":"Algantri","sequence":"first","affiliation":[{"name":"Department of Anatomy, Kulliyyah of Medicine, Widad University College, BIM Point, Bandar Indera Mahkota, Kuantan,Pahang, 25200, Malaysia"},{"name":"Department of Basic Medical Science, Kulliyyah of Medicine, International IslamicUniversity Malaysia, Bandar Indera Mahkota, Kuantan, Pahang, 25200, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Science, Kulliyyah of Medicine, International IslamicUniversity Malaysia, Bandar Indera Mahkota, Kuantan, Pahang, 25200, Malaysia"},{"name":"Clinical Pharmacology Department,Menoufia Medical School, Menoufia University, Menoufia, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Hamzah Mohd","family":"Nasir","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Kulliyyah ofScience, International Islamic University Malaysia, Bandar Indera Mahkota, Kuantan, 25200, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rahman Mahmoud Fata","family":"Nahas","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Kulliyyah of Pharmacy, International Islamic University Malaysia, Bandar Indera Mahkota,Kuantan, Pahang, 25200, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/mds.26354","volume":"30","author":"Lorraine V.","year":"2015","unstructured":"Lorraine V.; Disease-modifying strategies for Parkinson's disease. Mov Disord  2015,30(11),1442","journal-title":"Mov Disord"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ana.21995","volume":"67","author":"Cheng   U.C.","year":"2010","unstructured":"Cheng U.C.; Ulane C.M.; Burke R.E.; Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol  2010,67(6),715","journal-title":"Ann Neurol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ncl.2009.04.004.5","volume":"27","author":"Anthony H.V.","year":"2009","unstructured":"Anthony H.V.; Etiology and pathogenesis of Parkinson disease. Neurol Clin  2009,27(3),583","journal-title":"Neurol Clin"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"Braak H.","year":"2003","unstructured":"Braak H.; Tredici K.D.; R\u00fcb U.; de Vos R.A.I.; Jansen S.E.N.H.; Braak E.; Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging  2003,24(2),197-211","journal-title":"Neurobiol Aging"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1759091418777438","DOI":"10.1177\/1759091418777438","volume":"10","author":"Zeng X.S.","year":"2018","unstructured":"Zeng X.S.; Geng W.S.; Jia J.J.; Neurotoxin-induced animal models of Parkinson disease: Pathogenic mechanism and assessment. ASN Neuro  2018,10(1),1759091418777438","journal-title":"ASN Neuro"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/toxsci\/kfr239","volume":"124","author":"Cannon J.R.","year":"2011","unstructured":"Cannon J.R.; Greenamyre J.T.; The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol Sci  2011,124(2),225-250","journal-title":"Toxicol Sci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-genom-082410-101440","volume":"12","author":"Martin I.","year":"2011","unstructured":"Martin I.; Dawson V.L.; Dawson T.M.; Recent advances in the genetics of Parkinson\u2019s disease. Annu Rev Genomics Hum Genet  2011,12(1),301-325","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1468-1331.2008.02055.x","volume":"15","author":"Schapira A.H.V.","year":"2008","unstructured":"Schapira A.H.V.; Progress in neuroprotection in Parkinson\u2019s disease. Eur J Neurol  2008,15(s1),5-13","journal-title":"Eur J Neurol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrneurol.2014.226","volume":"11","author":"Athauda D.","year":"2015","unstructured":"Athauda D.; Foltynie T.; The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat Rev Neurol  2015,11(1),25-40","journal-title":"Nat Rev Neurol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1007\/s12264-017-0159-5","volume":"33","author":"Reichmann H.","year":"2017","unstructured":"Reichmann H.; Premotor diagnosis of Parkinson\u2019s disease. Neurosci Bull  2017,33(5),526-534","journal-title":"Neurosci Bull"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1002\/ana.10488","volume":"53","author":"Stocchi F.","year":"2003","unstructured":"Stocchi F.; Olanow C.W.; Neuroprotection in Parkinson\u2019s disease: Clinical trials. Ann Neurol  2003,53(S3),S87-S99","journal-title":"Ann Neurol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1002\/mds.22218","volume":"23","author":"Olanow C.W.","year":"2008","unstructured":"Olanow C.W.; Hauser R.A.; Jankovic J.; Langston W.; Lang A.; Poewe W.; Tolosa E.; Stocchi F.; Melamed E.; Eyal E.; Rascol O.; A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson\u2019s disease (the ADAGIO study): Rationale, design, and baseline characteristics. Mov Disord  2008,23(15),2194-2201","journal-title":"Mov Disord"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1749-6632.1992.tb24523.x","volume":"648","author":"German D.C.","year":"1992","unstructured":"German D.C.; Manaye K.F.; Sonsalla P.K.; Brooks B.A.; Midbrain dopaminergic cell loss in Parkinson\u2019s disease and MPTP-induced parkinsonism: Sparing of calbindin-D28k-containing cells. Ann N Y Acad Sci  1992,648(1),42-62","journal-title":"Ann N Y Acad Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.31887\/DCNS.2004.6.3\/galexander","volume":"6","author":"Alexander G.E.","year":"2004","unstructured":"Alexander G.E.; Biology of Parkinson\u2019s disease: Pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues Clin Neurosci  2004,6(3),259-280","journal-title":"Dialogues Clin Neurosci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40035-017-0099-z","volume":"6","author":"Maiti P.","year":"2017","unstructured":"Maiti P.; Manna J.; Dunbar G.L.; Current understanding of the molecular mechanisms in Parkinson\u2019s disease: Targets for potential treatments. Transl Neurodegener  2017,6(1),28","journal-title":"Transl Neurodegener"},{"key":"ref=16","first-page":"373","volume":"47","author":"Gupta Y.K.","year":"2003","unstructured":"Gupta Y.K.; Gupta M.; Kohli K.; Neuroprotective role of melatonin in oxidative stress vulnerable brain. Indian J Physiol Pharmacol  2003,47(4),373-386","journal-title":"Indian J Physiol Pharmacol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/10408360290795547","volume":"39","author":"Guetens G.","year":"2002","unstructured":"Guetens G.; Boeck G.D.; Highley M.; van Oosterom A.T.; de Bruijn E.A.; Oxidative DNA damage: Biological significance and methods of analysis. Crit Rev Clin Lab Sci  2002,39(4-5),331-457","journal-title":"Crit Rev Clin Lab Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1749-6632.1999.tb07985.x","volume":"890","author":"Skaper S.D.","year":"1999","unstructured":"Skaper S.D.; Floreani M.; Ceccon M.; Facci L.; Giusti P.; Excitotoxicity, oxidative stress, and the neuroprotective potential of melatonin. Ann N Y Acad Sci  1999,890(1),107-118","journal-title":"Ann N Y Acad Sci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"7212","DOI":"10.1523\/JNEUROSCI.0711-11.2011","volume":"31","author":"Kim-Han J.S.","year":"2011","unstructured":"Kim-Han J.S.; Antenor-Dorsey J.A.; O\u2019Malley K.L.; The parkinsonian mimetic, MPP+, specifically impairs mitochondrial transport in dopamine axons. J Neurosci  2011,31(19),7212-7221","journal-title":"J Neurosci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/S1474-4422(11)70227-7","volume":"10","author":"Chesselet M-F, D","year":"2011","unstructured":"Chesselet M-F, D;  Modelling of Parkinson's disease in mice. Lancet Neurol  2011,10(12),1108","journal-title":"Lancet Neurol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fnagi.2010.00012","volume":"2","author":"Wang X.","year":"2010","unstructured":"Wang X.; Michaelis E.K.; Selective neuronal vulnerability to oxidative stress in the brain. Front Aging Neurosci  2010,2,12","journal-title":"Front Aging Neurosci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"w13659","DOI":"10.4414\/smw.2012.13659","volume":"142","author":"Brieger K.","year":"2012","unstructured":"Brieger K.; Schiavone S.; Miller J.; Krause K.H.; Reactive oxygen species: From health to disease. Swiss Med Wkly  2012,142(3334),w13659","journal-title":"Swiss Med Wkly"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"11783","DOI":"10.3390\/ijms130911783","volume":"13","author":"Lee D.H.","year":"2012","unstructured":"Lee D.H.; Gold R.; Linker R.A.; Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: Therapeutic modulation via fumaric acid esters. Int J Mol Sci  2012,13(9),11783-11803","journal-title":"Int J Mol Sci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10654-011-9581-6","volume":"26","author":"Wirdefeldt K.","year":"2011","unstructured":"Wirdefeldt K.; Adami H.O.; Cole P.; Trichopoulos D.; Mandel J.; Epidemiology and etiology of Parkinson\u2019s disease: A review of the evidence. Eur J Epidemiol  2011,26(S1),1-58","journal-title":"Eur J Epidemiol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/PL00007400","volume":"99","author":"Wakabayashi K.","year":"2000","unstructured":"Wakabayashi K.; Hayashi S.; Yoshimoto M.; Kudo H.; Takahashi H.; NACP\/\u03b1-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson\u2019s disease brains. Acta Neuropathol  2000,99(1),14-20","journal-title":"Acta Neuropathol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"a008888","DOI":"10.1101\/cshperspect.a008888","volume":"2","author":"Klein C.","year":"2012","unstructured":"Klein C.; Westenberger A.; Genetics of Parkinson\u2019s disease. Cold Spring Harb Perspect Med  2012,2(1),a008888","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.neuron.2016.03.038","volume":"90","author":"Michel P.P.","year":"2016","unstructured":"Michel P.P.; Hirsch E.C.; Hunot S.; Understanding dopaminergic cell death pathways in Parkinson disease. Neuron  2016,90(4),675-691","journal-title":"Neuron"},{"key":"ref=28","first-page":"590","volume":"33","author":"Goldenberg M.M.","year":"2008","unstructured":"Goldenberg M.M.; Medical management of Parkinson\u2019s disease. PandT  2008,33(10),590-606","journal-title":"PandT"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/j.1471-4159.1990.tb02325.x","volume":"54","author":"Schapira A.H.V.","year":"1990","unstructured":"Schapira A.H.V.; Cooper J.M.; Dexter D.; Clark J.B.; Jenner P.; Marsden C.D.; Mitochondrial complex I deficiency in Parkinson\u2019s disease. J Neurochem  1990,54(3),823-827","journal-title":"J Neurochem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.3390\/nu14204326","volume":"14","author":"Gherardi G.","year":"2022","unstructured":"Gherardi G.; Corbioli G.; Ruzza F.; Rizzuto R.; CoQ10 and resveratrol effects to ameliorate aged-related mitochondrial dysfunctions. Nutrients  2022,14(20),4326","journal-title":"Nutrients"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/sj.bjp.0707167","volume":"150","author":"Whitton P.S.","year":"2007","unstructured":"Whitton P.S.; Inflammation as a causative factor in the aetiology of Parkinson\u2019s disease. Br J Pharmacol  2007,150(8),963-976","journal-title":"Br J Pharmacol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/antiox9090824","volume":"9","author":"Siracusa R.","year":"2020","unstructured":"Siracusa R.; Scuto M.; Fusco R.; Trovato A.; Ontario M.L.; Crea R.; Di Paola R.; Cuzzocrea S.; Calabrese V.; Anti-inflammatory and anti-oxidant activity of Hidrox\u00ae in rotenone-induced Parkinson\u2019s disease in mice. Antioxidants  2020,9(9),824","journal-title":"Antioxidants"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1126\/science.8493557","volume":"260","author":"Lin L.F.H.","year":"1993","unstructured":"Lin L.F.H.; Doherty D.H.; Lile J.D.; Bektesh S.; Collins F.; GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science  1993,260(5111),1130-1132","journal-title":"Science"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3389\/fneur.2018.00457","volume":"9","author":"Penttinen A.M.","year":"2018","unstructured":"Penttinen A.M.; Parkkinen I.; Voutilainen M.H.; Koskela M.; B\u00e4ck S.; Their A.; Richie C.T.; Domanskyi A.; Harvey B.K.; Tuominen R.K.; Nevalaita L.; Saarma M.; Airavaara M.; Pre-\u03b1-pro-GDNF and pre-\u03b2-pro-GDNF isoforms are neuroprotective in the 6-hydroxydopamine rat model of Parkinson\u2019s disease. Front Neurol  2018,9,457","journal-title":"Front Neurol"},{"key":"ref=35","first-page":"747","volume":"22","author":"Stefanis L.","year":"2012","unstructured":"Stefanis L.; Alpha-synuclein in Parkinson\u2019s disease: A neuropathological review. Brain Pathol  2012,22(6),747-763","journal-title":"Brain Pathol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"105527","DOI":"10.1016\/j.nbd.2021.105527","volume":"160","author":"Hu S.","year":"2021","unstructured":"Hu S.; Tan J.; Qin L.; Lv L.; Yan W.; Zhang H.; Tang B.; Wang C.; Molecular chaperones and Parkinson\u2019s disease. Neurobiol Dis  2021,160,105527","journal-title":"Neurobiol Dis"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1089\/ars.2010.3521","volume":"14","author":"Surmeier D.J.","year":"2011","unstructured":"Surmeier D.J.; Guzman J.N.; Sanchez-Padilla J.; Goldberg J.A.; The origins of oxidant stress in Parkinson\u2019s disease and therapeutic strategies. Antioxid Redox Signal  2011,14(7),1289-1301","journal-title":"Antioxid Redox Signal"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-pharmtox-010818-021214","volume":"59","author":"Liss B.","year":"2019","unstructured":"Liss B.; Striessnig J.; The potential of L-type calcium channels as a drug target for neuroprotective therapy in Parkinson\u2019s disease. Annu Rev Pharmacol Toxicol  2019,59(1),263-289","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3390\/nu10091139","volume":"10","author":"Johnson S.L.","year":"2018","unstructured":"Johnson S.L.; Park H.Y.; DaSilva N.A.; Vattem D.A.; Ma H.; Seeram N.P.; Levodopa-reduced Mucuna pruriens seed extract shows neuroprotective effects against Parkinson\u2019s disease in murine microglia and human neuroblastoma cells, Caenorhabditis elegans, and Drosophila melanogaster. Nutrients  2018,10(9),1139","journal-title":"Nutrients"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1080\/14656566.2020.1805432","volume":"21","author":"Cerri S.","year":"2020","unstructured":"Cerri S.; Blandini F.; An update on the use of non-ergot dopamine agonists for the treatment of Parkinson\u2019s disease. Expert Opin Pharmacother  2020,21(18),2279-2291","journal-title":"Expert Opin Pharmacother"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/ijms17060904","volume":"17","author":"Sarkar S.","year":"2016","unstructured":"Sarkar S.; Raymick J.; Imam S.; Neuroprotective and therapeutic strategies against Parkinson\u2019s disease: Recent perspectives. Int J Mol Sci  2016,17(6),904","journal-title":"Int J Mol Sci"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/md17020108","volume":"17","author":"Paudel P.","year":"2019","unstructured":"Paudel P.; Seong S.H.; Wu S.; Park S.; Jung H.A.; Choi J.S.; Eckol as a potential therapeutic against neurodegenerative diseases targeting dopamine D3\/D4 receptors. Mar Drugs  2019,17(2),108","journal-title":"Mar Drugs"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fneur.2011.00068","volume":"2","author":"Seidl S.E.","year":"2011","unstructured":"Seidl S.E.; Potashkin J.A.; The promise of neuroprotective agents in Parkinson\u2019s disease. Front Neurol  2011,2,68","journal-title":"Front Neurol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.4103\/1673-5374.237108","volume":"13","author":"Peplow P.V.","year":"2018","unstructured":"Peplow P.V.; Martinez B.; Neuroprotection by immunomodulatory agents in animal models of Parkinson\u2019s disease. Neural Regen Res  2018,13(9),1493-1506","journal-title":"Neural Regen Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3233\/JPD-212976","volume":"12","author":"Tan Y.Y.","year":"2022","unstructured":"Tan Y.Y.; Jenner P.; Chen S.D.; Monoamine Oxidase-B inhibitors for the treatment of Parkinson\u2019s disease: Past, present, and future. J Parkinsons Dis  2022,12(2),477-493","journal-title":"J Parkinsons Dis"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2174\/1871527321666211231100255","volume":"22","author":"Koh R.Y.","year":"2023","unstructured":"Koh R.Y.; Chew Z.X.; Lim C.L.; Ng K.Y.; Chye S.M.; Ling A.P.K.; The role of monoamine oxidase b inhibitors in the treatment of Parkinson\u2019s disease - An update. CNS Neurol Disord Drug Targets  2023,22(3),329-352","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4103\/1673-5374.375299","volume":"19","author":"Alborghetti M.","year":"2024","unstructured":"Alborghetti M.; Bianchini E.; De Carolis L.; Galli S.; Pontieri F.E.; Rinaldi D.; Type-B monoamine oxidase inhibitors in neurological diseases. Neural Regen Res  2024,19(1),16-21","journal-title":"Neural Regen Res"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-56015-1_238-2","author":"Nagatsu T.","year":"2020","unstructured":"Nagatsu T.; Nakashima A.; Monoamine oxidase inhibitor (MAO-I)-mediated neuroprotection for treating Parkinson\u2019s disease. NeuroPsychopharmacotherapy  2020,1-21","journal-title":"NeuroPsychopharmacotherapy"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/jnr.1208","volume":"66","author":"Li Y.","year":"2001","unstructured":"Li Y.; Liu L.; Barger S.W.; Mrak R.E.; Griffin W.S.T.; Vitamin E suppression of microglial activation is neuroprotective. J Neurosci Res  2001,66(2),163-170","journal-title":"J Neurosci Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0006-8993(00)03296-0","volume":"892","author":"Roghani M.","year":"2001","unstructured":"Roghani M.; Behzadi G.; Neuroprotective effect of vitamin E on the early model of Parkinson\u2019s disease in rat: Behavioral and histochemical evidence11Published on the World Wide Web 3 January 2001. Brain Res  2001,892(1),211-217","journal-title":"Brain Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0165-0173(93)90010-W","volume":"18","author":"Gr\u00fcnewald R.A.","year":"1993","unstructured":"Gr\u00fcnewald R.A.; Ascorbic acid in the brain. Brain Res Rev  1993,18(1),123-133","journal-title":"Brain Res Rev"},{"key":"ref=52","doi-asserted-by":"crossref","unstructured":"Seidl, S.E.; Potashkin, J.A. The promise of neuroprotective agents in Parkinson\u2019s disease. Front. Neurol., 2011, 2, 68. https:\/\/dx.doi.org\/10.3389\/fneur.2011.00068","DOI":"10.3389\/fneur.2011.00068"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jchemneu.2004.08.006","volume":"29","author":"Eyles D.W.","year":"2005","unstructured":"Eyles D.W.; Smith S.; Kinobe R.; Hewison M.; McGrath J.J.; Distribution of the Vitamin D receptor and 1\u03b1-hydroxylase in human brain. J Chem Neuroanat  2005,29(1),21-30","journal-title":"J Chem Neuroanat"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/iub.91","volume":"60","author":"Wojda U.","year":"2008","unstructured":"Wojda U.; Salinska E.; Kuznicki J.; Calcium ions in neuronal degeneration. IUBMB Life  2008,60(9),575-590","journal-title":"IUBMB Life"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nm850","volume":"9","author":"Gill S.S.","year":"2003","unstructured":"Gill S.S.; Patel N.K.; Hotton G.R.; O\u2019Sullivan K.; McCarter R.; Bunnage M.; Brooks D.J.; Svendsen C.N.; Heywood P.; Direct brain infusion of glial cell line\u2013derived neurotrophic factor in Parkinson disease. Nat Med  2003,9(5),589-595","journal-title":"Nat Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"e62040","DOI":"10.1371\/journal.pone.0062040","volume":"8","author":"Orme R.P.","year":"2013","unstructured":"Orme R.P.; Bhangal M.S.; Fricker R.A.; Calcitriol imparts neuroprotection in vitro to midbrain dopaminergic neurons by upregulating GDNF expression. PLoS One  2013,8(4),e62040","journal-title":"PLoS One"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1073\/pnas.0610204104","volume":"104","author":"Scherzer C.R.","year":"2007","unstructured":"Scherzer C.R.; Eklund A.C.; Morse L.J.; Liao Z.; Locascio J.J.; Fefer D.; Schwarzschild M.A.; Schlossmacher M.G.; Hauser M.A.; Vance J.M.; Sudarsky L.R.; Molecular markers of early Parkinson\u2019s disease based on gene expression in blood. Proc Nat Acad Sci  2007,104(3),955-60","journal-title":"Proc Nat Acad Sci"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.neuroscience.2022.03.039","volume":"492","author":"Manjari S.K.V.","year":"2022","unstructured":"Manjari S.K.V.; Maity S.; Poornima R.; Yau S.Y.; Vaishali K.; Stellwagen D.; Komal P.; Restorative action of vitamin D3 on motor dysfunction through enhancement of neurotrophins and antioxidant expression in the striatum. Neuroscience  2022,492,67-81","journal-title":"Neuroscience"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/1531-8257(199901)14:1<21::AID-MDS1006>3.0.CO;2-Y","volume":"14","author":"Anderson C.","year":"1999","unstructured":"Anderson C.; Checkoway H.; Franklin G.M.; Beresford S.; Smith-Weller T.; Swanson P.D.; Dietary factors in Parkinson\u2019s disease: The role of food groups and specific foods. Mov Disord  1999,14(1),21-27","journal-title":"Mov Disord"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/978-3-030-46459-2_15","author":"Dewanjee S","year":"2021","unstructured":"Dewanjee S; Zia-Ul-Haq M; Riaz M; Sarkhel S; Chakraborty P; Ahmed S; Carotenoids as antiparkinson agents. Carotenoids: Structure and Function in the Human Body  2021,533-5554","journal-title":"Carotenoids: Structure and Function in the Human Body"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1590\/S0100-879X2003001000019","volume":"36","author":"Coimbra C.G.","year":"2003","unstructured":"Coimbra C.G.; Junqueira V.B.C.; High doses of riboflavin and the elimination of dietary red meat promote the recovery of some motor functions in Parkinson\u2019s disease patients. Braz J Med Biol Res  2003,36(10),1409-1417","journal-title":"Braz J Med Biol Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1017\/S0007114510001005","volume":"104","author":"Murakami K.","year":"2010","unstructured":"Murakami K.; Miyake Y.; Sasaki S.; Tanaka K.; Fukushima W.; Kiyohara C.; Tsuboi Y.; Yamada T.; Oeda T.; Miki T.; Kawamura N.; Sakae N.; Fukuyama H.; Hirota Y.; Nagai M.; Dietary intake of folate, vitamin B, vitamin B and riboflavin and risk of Parkinson\u2019s disease: a case\u2013control study in Japan. Br J Nutr  2010,104(5),757-764","journal-title":"Br J Nutr"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.neulet.2013.09.049","volume":"570","author":"Alhebshi A.H.","year":"2014","unstructured":"Alhebshi A.H.; Odawara A.; Gotoh M.; Suzuki I.; Thymoquinone protects cultured hippocampal and human induced pluripotent stem cells-derived neurons against \u03b1-synuclein-induced synapse damage. Neurosci Lett  2014,570,126-131","journal-title":"Neurosci Lett"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.neuroscience.2008.11.051","volume":"159","author":"Alladi P.A.","year":"2009","unstructured":"Alladi P.A.; Mahadevan A.; Yasha T.C.; Raju T.R.; Shankar S.K.; Muthane U.; Absence of age-related changes in nigral dopaminergic neurons of Asian Indians: Relevance to lower incidence of Parkinson\u2019s disease. Neuroscience  2009,159(1),236-245","journal-title":"Neuroscience"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1017\/S0007114510005817","volume":"106","author":"Mythri R.B.","year":"2011","unstructured":"Mythri R.B.; Veena J.; Harish G.; Rao S.B.S.; Srinivas B.M.M.; Chronic dietary supplementation with turmeric protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-mediated neurotoxicity in vivo : Implications for Parkinson\u2019s disease. Br J Nutr  2011,106(1),63-72","journal-title":"Br J Nutr"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/00001813-200503000-00005","volume":"16","author":"Adams B.K.","year":"2005","unstructured":"Adams B.K.; Cai J.; Armstrong J.; Herold M.; Lu Y.J.; Sun A.; Snyder J.P.; Liotta D.C.; Jones D.P.; Shoji M.; EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs  2005,16(3),263-275","journal-title":"Anticancer Drugs"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S0090-9556(24)15211-7","volume":"27","author":"Pan M.H.","year":"1999","unstructured":"Pan M.H.; Huang T.M.; Lin J.K.; Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos  1999,27(4),486-494","journal-title":"Drug Metab Dispos"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3390\/antiox9070600","volume":"9","author":"Mursaleen L.","year":"2020","unstructured":"Mursaleen L.; Noble B.; Chan S.H.Y.; Somavarapu S.; Zariwala M.G.; N-Acetylcysteine nanocarriers protect against oxidative stress in a cellular model of Parkinson\u2019s disease. Antioxidants  2020,9(7),600","journal-title":"Antioxidants"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/978-3-319-42139-1_9","author":"Esteves A.R.","year":"2016","unstructured":"Esteves A.R.; Silva D.F.; Mitochondrial therapeutic approaches in Parkinson\u2019s disease. Mitochondrial Mechanisms of Degeneration and Repair in Parkinson's Disease  2016,183-205","journal-title":"Mitochondrial Mechanisms of Degeneration and Repair in Parkinson's Disease"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11011-022-00990-x","volume":"38","author":"Brasil F.B.","year":"2023","unstructured":"Brasil F.B.; de Almeida F.J.S.; Luckachaki M.D.; Dall\u2019Oglio E.L.; de Oliveira M.R.; The isothiocyanate sulforaphane prevents mitochondrial impairment and neuroinflammation in the human dopaminergic SH-SY5Y and in the mouse microglial BV2 cells: Role for heme oxygenase-1. Metab Brain Dis  2023,38(2),419-435","journal-title":"Metab Brain Dis"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.3390\/antiox10121935","volume":"10","author":"Lin K.J.","year":"2021","unstructured":"Lin K.J.; Wang T.J.; Chen S.D.; Lin K.L.; Liou C.W.; Lan M.Y.; Chuang Y.C.; Chuang J.H.; Wang P.W.; Lee J.J.; Wang F.S.; Lin H.Y.; Lin T.K.; Two birds one stone: The neuroprotective effect of antidiabetic agents on parkinson disease\u2014focus on sodium-glucose cotransporter 2 (sglt2) inhibitors. Antioxidants  2021,10(12),1935","journal-title":"Antioxidants"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.2337\/dc11-1584","volume":"34","author":"Cereda E.","year":"2011","unstructured":"Cereda E.; Barichella M.; Pedrolli C.; Klersy C.; Cassani E.; Caccialanza R.; Pezzoli G.; Diabetes and risk of Parkinson\u2019s disease: A systematic review and meta-analysis. Diabetes Care  2011,34(12),2614-2623","journal-title":"Diabetes Care"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/mds.27526","volume":"33","author":"Ibrahim M.N.","year":"2018","unstructured":"Ibrahim M.N.; Ramli R.; Kutty K.S.; Shah S.A.; Earlier onset of motor complications in Parkinson\u2019s patients with comorbid diabetes mellitus. Mov Disord  2018,33(12),1967-1968","journal-title":"Mov Disord"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1002\/mds.27128","volume":"32","author":"Brakedal B.","year":"2017","unstructured":"Brakedal B.; Fl\u00f8nes I.; Reiter S.F.; Torkildsen \u00d8.; D\u00f6lle C.; Assmus J.; Haugarvoll K.; Tzoulis C.; Glitazone use associated with reduced risk of Parkinson\u2019s disease. Mov Disord  2017,32(11),1594-1599","journal-title":"Mov Disord"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/WNR.0000000000000548","volume":"27","author":"Cao L.","year":"2016","unstructured":"Cao L.; Li D.; Feng P.; Li L.; Xue G.F.; Li G.; H\u00f6lscher C.; A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson\u2019s disease by reducing chronic inflammation in the brain. Neuroreport  2016,27(6),384-391","journal-title":"Neuroreport"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1007\/s00125-017-4349-5","volume":"60","author":"Valencia W.M.","year":"2017","unstructured":"Valencia W.M.; Palacio A.; Tamariz L.; Florez H.; Metformin and ageing: Improving ageing outcomes beyond glycaemic control. Diabetologia  2017,60(9),1630-1638","journal-title":"Diabetologia"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3389\/fnagi.2018.00227","volume":"10","author":"Lin Y.","year":"2018","unstructured":"Lin Y.; Wang K.; Ma C.; Wang X.; Gong Z.; Zhang R.; Zang D.; Cheng Y.; Evaluation of metformin on cognitive improvement in patients with non-dementia vascular cognitive impairment and abnormal glucose metabolism. Front Aging Neurosci  2018,10,227","journal-title":"Front Aging Neurosci"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3389\/fendo.2018.00400","volume":"9","author":"Rotermund C.","year":"2018","unstructured":"Rotermund C.; Machetanz G.; Fitzgerald J.C.; The therapeutic potential of metformin in neurodegenerative diseases. Front Endocrinol  2018,9,400","journal-title":"Front Endocrinol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"pyw047","DOI":"10.1093\/ijnp\/pyw047","volume":"19","author":"Lu M.","year":"2016","unstructured":"Lu M.; Su C.; Qiao C.; Bian Y.; Ding J.; Hu G.; Metformin prevents dopaminergic neuron death in MPTP\/P-induced mouse model of Parkinson\u2019s disease via autophagy and mitochondrial ROS clearance. Int J Neuropsychopharmacol  2016,19(9),pyw047","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s10787-023-01192-2","volume":"31","author":"Alrouji M.","year":"2023","unstructured":"Alrouji M.; Al-Kuraishy H.M.; Al-Gareeb A.I.; Saad H.M.; Batiha G.E.S.; A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson\u2019s disease: Beneficial or detrimental effects. Inflammopharmacology  2023,31(2),673-688","journal-title":"Inflammopharmacology"},{"key":"ref=81","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1006-5725.2023.15.006","volume":"39","author":"Junrong H.E.","year":"2023","unstructured":"Junrong H.E.; Zai L.I.; Xipei C.H.; Neuroprotective effect of ibuprofen on ischemic stroke rats and its effect on Nrf2\/SLC7A1I\/GPX4 signal pathway. J Practical Med  2023,39(5)","journal-title":"J Practical Med"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"106043","DOI":"10.1016\/j.parkreldis.2024.106043","volume":"126","author":"Finsterer J.","year":"2024","unstructured":"Finsterer J.; Almeida A.C.G.; Chaddad-Neto F.; Scorza F.A.; Statin therapy in Parkinson\u2019s disease cuts mortality. Parkinsonism Relat Disord  2024,126,106043","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=83","first-page":"53","volume":"7","author":"Bhardwaj R.","year":"2018","unstructured":"Bhardwaj R.; Deshmukh R.; Neurotrophic factors and Parkinson\u2019s disease. Clin Investig  2018,7(4),53-62","journal-title":"Clin Investig"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.baga.2013.09.001","volume":"3","author":"Carrillo-Mora P.","year":"2013","unstructured":"Carrillo-Mora P.; Silva-Adaya D.; Villase\u00f1or-Aguayo K.; Glutamate in Parkinson\u2019s disease: Role of antiglutamatergic drugs. Basal Ganglia  2013,3(3),147-157","journal-title":"Basal Ganglia"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"17562864241252713","DOI":"10.1177\/17562864241252713","volume":"17","author":"Lin J.","year":"2024","unstructured":"Lin J.; Pang D.; Li C.; Ou R.; Yu Y.; Cui Y.; Huang J.; Shang H.; Calcium channel blockers and Parkinson\u2019s disease: A systematic review and meta-analysis. Ther Adv Neurol Disord  2024,17,17562864241252713","journal-title":"Ther Adv Neurol Disord"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"47284","DOI":"10.18632\/oncotarget.17618","volume":"8","author":"Wang Q.M.","year":"2017","unstructured":"Wang Q.M.; Xu Y.Y.; Liu S.; Ma Z.G.; Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice. Oncotarget  2017,8(29),47284-47295","journal-title":"Oncotarget"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s11064-021-03262-9","volume":"46","author":"Zeng X.","year":"2021","unstructured":"Zeng X.; An H.; Yu F.; Wang K.; Zheng L.; Zhou W.; Bao Y.; Yang J.; Shen N.; Huang D.; Benefits of iron chelators in the treatment of Parkinson\u2019s disease. Neurochem Res  2021,46(5),1239-1251","journal-title":"Neurochem Res"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1111\/j.1471-4159.2009.06074.x","volume":"109","author":"Yang L.","year":"2009","unstructured":"Yang L.; Calingasan N.Y.; Wille E.J.; Cormier K.; Smith K.; Ferrante R.J.; Flint B.M.; Combination therapy with Coenzyme Q and creatine produces additive neuroprotective effects in models of Parkinson\u2019s and Huntington\u2019s diseases. J Neurochem  2009,109(5),1427-1439","journal-title":"J Neurochem"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/sj.ejcn.1602788","volume":"62","author":"S\u00e4ksj\u00e4rvi K.","year":"2008","unstructured":"S\u00e4ksj\u00e4rvi K.; Knekt P.; Rissanen H.; Laaksonen M.A.; Reunanen A.; M\u00e4nnist\u00f6 S.; Prospective study of coffee consumption and risk of Parkinson\u2019s disease. Eur J Clin Nutr  2008,62(7),908-915","journal-title":"Eur J Clin Nutr"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.expneurol.2010.02.007","volume":"223","author":"Kachroo A.","year":"2010","unstructured":"Kachroo A.; Irizarry M.C.; Schwarzschild M.A.; Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Exp Neurol  2010,223(2),657-661","journal-title":"Exp Neurol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.parkreldis.2004.06.004","volume":"10","author":"Joghataie M.T.","year":"2004","unstructured":"Joghataie M.T.; Roghani M.; Negahdar F.; Hashemi L.; Protective effect of caffeine against neurodegeneration in a model of Parkinson\u2019s disease in rat: Behavioral and histochemical evidence. Parkinsonism Relat Disord  2004,10(8),465-468","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.pbb.2006.05.027","volume":"84","author":"Aguiar L.M.V.","year":"2006","unstructured":"Aguiar L.M.V.; Nobre H.V.; Mac\u00eado D.S.; Oliveira A.A.; Freitas R.M.; Vasconcelos S.M.; Cunha G.M.A.; Sousa F.C.F.; Viana G.S.B.; Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats. Pharmacol Biochem Behav  2006,84(3),415-419","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.neuroscience.2010.02.020","volume":"167","author":"Xu K.","year":"2010","unstructured":"Xu K.; Xu Y.H.; Chen J.F.; Schwarzschild M.A.; Neuroprotection by caffeine: Time course and role of its metabolites in the MPTP model of Parkinson\u2019s disease. Neuroscience  2010,167(2),475-481","journal-title":"Neuroscience"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0304-3940(02)00069-1","volume":"322","author":"Xu K.","year":"2002","unstructured":"Xu K.; Xu Y.H.; Chen J.F.; Schwarzschild M.A.; Caffeine\u2019s neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci Lett  2002,322(1),13-16","journal-title":"Neurosci Lett"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.bcp.2011.08.010","volume":"83","author":"Russo M.","year":"2012","unstructured":"Russo M.; Spagnuolo C.; Tedesco I.; Bilotto S.; Russo G.L.; The flavonoid quercetin in disease prevention and therapy: Facts and fancies. Biochem Pharmacol  2012,83(1),6-15","journal-title":"Biochem Pharmacol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"e909","DOI":"10.22086\/gmj.v0i0.909","volume":"6","author":"Russo M.","year":"2017","unstructured":"Russo M.; Spagnuolo C.; Tedesco I.; Bilotto S.; Russo G.L.; Protective effects of red onion (Allium cepa) ethanolic extract on learning and memory impairments in animal models of diabetes. Biochem Pharmacol  2017,6(3),e909","journal-title":"Biochem Pharmacol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"153","DOI":"10.5114\/bta.2022.116210","volume":"103","author":"Hegazy E.M.","year":"2022","unstructured":"Hegazy E.M.; Sabry A.; Khalil W.K.B.; Neuroprotective effects of onion and garlic root extracts against Alzheimer\u2019s disease in rats: Antimicrobial, histopathological, and molecular studies. BioTechnologia  2022,103(2),153-167","journal-title":"BioTechnologia"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1089\/jmf.2008.1400","volume":"12","author":"Hwang I.K.","year":"2009","unstructured":"Hwang I.K.; Lee C.H.; Yoo K.Y.; Choi J.H.; Park O.K.; Lim S.S.; Kang I.J.; Kwon D.Y.; Park J.; Yi J.S.; Bae Y.S.; Won M.H.; Neuroprotective effects of onion extract and quercetin against ischemic neuronal damage in the gerbil hippocampus. J Med Food  2009,12(5),990-995","journal-title":"J Med Food"},{"key":"ref=99","doi-asserted-by":"publisher","DOI":"10.54112\/bcsrj.v2021i1.53","volume":"2021","author":"Ashfaq F.","year":"2021","unstructured":"Ashfaq F.; Ali Q.; Haider M.A.; Hafeez M.M.; Malik A.; Therapeutic activities of garlic constituent phytochemicals. Biol Clin Sci Res J  2021,2021(1)","journal-title":"Biol Clin Sci Res J"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s11011-021-00705-8","volume":"36","author":"Bigham M.","year":"2021","unstructured":"Bigham M.; Mohammadipour A.; Hosseini M.; Malvandi A.M.; Ebrahimzadeh-Bideskan A.; Neuroprotective effects of garlic extract on dopaminergic neurons of substantia nigra in a rat model of Parkinson\u2019s disease: Motor and non-motor outcomes. Metab Brain Dis  2021,36(5),927-937","journal-title":"Metab Brain Dis"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3390\/toxins15050307","volume":"15","author":"Medalcho T.H.","year":"2023","unstructured":"Medalcho T.H.; Abegaz K.; Dessalegn E.; Mate J.; Aflatoxin B1 detoxification potentials of garlic, ginger, cardamom, black cumin, and saut\u00e9ing in ground spice mix red pepper products. Toxins  2023,15(5),307","journal-title":"Toxins"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1021\/jf0209185","volume":"51","author":"Abdel-Wahhab M.A.","year":"2003","unstructured":"Abdel-Wahhab M.A.; Aly S.E.; Antioxidants and radical scavenging properties of vegetable extracts in rats fed aflatoxin-contaminated diet. J Agric Food Chem  2003,51(8),2409-2414","journal-title":"J Agric Food Chem"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.3390\/molecules27103297","volume":"27","author":"Iftikhar A.","year":"2022","unstructured":"Iftikhar A.; Nausheen R.; Muzaffar H.; Naeem M.A.; Farooq M.; Khurshid M.; Almatroudi A.; Alrumaihi F.; Allemailem K.S.; Anwar H.; Potential therapeutic benefits of honey in neurological disorders: The role of polyphenols. Molecules  2022,27(10),3297","journal-title":"Molecules"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"308","DOI":"10.37358\/RC.20.9.8341","volume":"71","author":"Topal N.","year":"2020","unstructured":"Topal N.; Bulduk I.; Mut Z.; Bozodlu H.; Tosun Y.K.; Flowers, pollen and honey for use in the treatment of Parkinson\u2019s disease. Revista de Chimie  2020,71(9),308-319","journal-title":"Revista de Chimie"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"58","DOI":"10.2174\/1574885513666180529114546","volume":"14","author":"Ara G.","year":"2019","unstructured":"Ara G.; Afzal M.; Jyoti S.; Naz F.; Rahul ; Siddique Y.H.; Effect of Myricetin on the loss of dopaminergic neurons in the transgenic Drosophila model of Parkinson\u2019s disease. Curr Drug Ther  2019,14(1),58-64","journal-title":"Curr Drug Ther"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.jff.2018.04.018","volume":"45","author":"Huang B.","year":"2018","unstructured":"Huang B.; Liu J.; Ma D.; Chen G.; Wang W.; Fu S.; Myricetin prevents dopaminergic neurons from undergoing neuroinflammation-mediated degeneration in a lipopolysaccharide-induced Parkinson\u2019s disease model. J Funct Foods  2018,45,452-461","journal-title":"J Funct Foods"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.1021\/acs.jafc.6b01707","volume":"64","author":"Guo B.","year":"2016","unstructured":"Guo B.; Zheng C.; Cai W.; Cheng J.; Wang H.; Li H.; Sun Y.; Cui W.; Wang Y.; Han Y.; Lee S.M.Y.; Zhang Z.; Multifunction of chrysin in Parkinson\u2019s model: Anti-neuronal apoptosis, neuroprotection via activation of MEF2D, and inhibition of monoamine oxidase-B. J Agric Food Chem  2016,64(26),5324-5333","journal-title":"J Agric Food Chem"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/archneurol.2009.247","volume":"66","author":"Ascherio A.","year":"2009","unstructured":"Ascherio A.; LeWitt P.A.; Xu K.; Eberly S.; Watts A.; Matson W.R.; Marras C.; Kieburtz K.; Rudolph A.; Bogdanov M.B.; Schwid S.R.; Tennis M.; Tanner C.M.; Beal M.F.; Lang A.E.; Oakes D.; Fahn S.; Shoulson I.; Schwarzschild M.A.; Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol  2009,66(12),1460-1468","journal-title":"Arch Neurol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/(SICI)1097-4547(19980901)53:5<613::AID-JNR11>3.0.CO;2-1","volume":"53","author":"Yu Z.F.","year":"1998","unstructured":"Yu Z.F.; Bruce-Keller A.J.; Goodman Y.; Mattson M.P.; Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res  1998,53(5),613-625","journal-title":"J Neurosci Res"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/7697261","volume":"2018","author":"Xie Y.","year":"2018","unstructured":"Xie Y.; Zeng H.; Huang Z.; Xu H.; Fan Q.; Zhang Y.; Zheng B.; Effect of maternal administration of edible bird\u2019s nest on the learning and memory abilities of suckling offspring in mice. Neural Plast  2018,2018,1-13","journal-title":"Neural Plast"},{"key":"ref=111","first-page":"65","volume":"2","author":"Tai S.K.","year":"2017","unstructured":"Tai S.K.; Koh R.Y.; Ng K.Y.; Chye S.M.; A mini review on medicinal effects of edible bird\u2019s nest. Lett Health Biol Sci  2017,2(1),65-67","journal-title":"Lett Health Biol Sci"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3389\/fncel.2019.00363","volume":"13","author":"Miranda M.","year":"2019","unstructured":"Miranda M.; Morici J.F.; Zanoni M.B.; Bekinschtein P.; Brain-derived neurotrophic factor: A key molecule for memory in the healthy and the pathological brain. Front Cell Neurosci  2019,13,363","journal-title":"Front Cell Neurosci"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"865671","DOI":"10.3389\/fneur.2022.865671","volume":"13","author":"Loh S.P.","year":"2022","unstructured":"Loh S.P.; Cheng S.H.; Mohamed W.; Edible bird\u2019s nest as a potential cognitive enhancer. Front Neurol  2022,13,865671","journal-title":"Front Neurol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"7205082","DOI":"10.1155\/2017\/7205082","volume":"2017","author":"Hou Z.","year":"2017","unstructured":"Hou Z.; He P.; Imam M.U.; Qi J.; Tang S.; Song C.; Ismail M.; Edible bird\u2019s nest prevents menopause-related memory and cognitive decline in rats via increased hippocampal sirtuin-1 expression. Oxid Med Cell Longev  2017,2017(1),7205082","journal-title":"Oxid Med Cell Longev"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1089\/acm.2008.0367","volume":"15","author":"Qidwai W.","year":"2009","unstructured":"Qidwai W.; Hamza H.B.; Qureshi R.; Gilani A.; Effectiveness, safety, and tolerability of powdered Nigella sativa (kalonji) seed in capsules on serum lipid levels, blood sugar, blood pressure, and body weight in adults: Results of a randomized, double-blind controlled trial. J Altern Complement Med  2009,15(6),639-644","journal-title":"J Altern Complement Med"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12031-020-01733-2","volume":"71","author":"Tuo Q.","year":"2021","unstructured":"Tuo Q.; Zou J.; Lei P.; Rodent models of vascular cognitive impairment. J Mol Neurosci  2021,71(5),1-12","journal-title":"J Mol Neurosci"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S2221-1691(13)60075-1","volume":"3","author":"Ahmad A.","year":"2013","unstructured":"Ahmad A.; Husain A.; Mujeeb M.; Khan S.A.; Najmi A.K.; Siddique N.A.; Damanhouri Z.A.; Anwar F.; A review on therapeutic potential of Nigella sativa: A miracle herb. Asian Pac J Trop Biomed  2013,3(5),337-352","journal-title":"Asian Pac J Trop Biomed"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.pharep.2017.03.002","volume":"69","author":"Hosseinian S.","year":"2017","unstructured":"Hosseinian S.; Rad A.K.; Bideskan A.E.; Soukhtanloo M.; Sadeghnia H.; Shafei M.N.; Motejadded F.; Mohebbati R.; Shahraki S.; Beheshti F.; Thymoquinone ameliorates renal damage in unilateral ureteral obstruction in rats. Pharmacol Rep  2017,69(4),648-657","journal-title":"Pharmacol Rep"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.toxlet.2017.05.018","volume":"276","author":"Ebrahimi S.S.","year":"2017","unstructured":"Ebrahimi S.S.; Oryan S.; Izadpanah E.; Hassanzadeh K.; Thymoquinone exerts neuroprotective effect in animal model of Parkinson\u2019s disease. Toxicol Lett  2017,276,108-114","journal-title":"Toxicol Lett"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.fct.2015.05.022","volume":"83","author":"Ghosh S.","year":"2015","unstructured":"Ghosh S.; Banerjee S.; Sil P.C.; The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: A recent update. Food Chem Toxicol  2015,83,111-124","journal-title":"Food Chem Toxicol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"11248","DOI":"10.3390\/ijms222011248","volume":"22","author":"Nebrisi E.E.","year":"2021","unstructured":"Nebrisi E.E.; Neuroprotective activities of curcumin in Parkinson\u2019s disease: A review of the literature. Int J Mol Sci  2021,22(20),11248","journal-title":"Int J Mol Sci"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"318","DOI":"10.2174\/1389201015666140617101332","volume":"15","author":"Renaud J.","year":"2014","unstructured":"Renaud J.; Martinoli M.G.; Resveratrol as a protective molecule for neuroinflammation: A review of mechanisms. Curr Pharm Biotechnol  2014,15(4),318-329","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jnutbio.2009.02.004","volume":"21","author":"Chao J.","year":"2010","unstructured":"Chao J.; Li H.; Cheng K.W.; Yu M.S.; Chang R.C.C.; Wang M.; Protective effects of pinostilbene, a resveratrol methylated derivative, against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. J Nutr Biochem  2010,21(6),482-489","journal-title":"J Nutr Biochem"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejphar.2008.10.005","volume":"600","author":"Jin F.","year":"2008","unstructured":"Jin F.; Wu Q.; Lu Y.F.; Gong Q.H.; Shi J.S.; Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson\u2019s disease in rats. Eur J Pharmacol  2008,600(1-3),78-82","journal-title":"Eur J Pharmacol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.bcp.2006.11.003","volume":"73","author":"Okawara M.","year":"2007","unstructured":"Okawara M.; Katsuki H.; Kurimoto E.; Shibata H.; Kume T.; Akaike A.; Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults. Biochem Pharmacol  2007,73(4),550-560","journal-title":"Biochem Pharmacol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/1472-6882-12-196","volume":"12","author":"Lee K.W.","year":"2012","unstructured":"Lee K.W.; Jung S.Y.; Choi S.M.; Yang E.J.; Effects of ginsenoside Re on LPS-induced inflammatory mediators in BV2 microglial cells. BMC Complement Altern Med  2012,12(1),196","journal-title":"BMC Complement Altern Med"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5142\/jgr.2013.37.8","volume":"37","author":"Kim H.J.","year":"2013","unstructured":"Kim H.J.; Kim P.; Shin C.Y.; A comprehensive review of the therapeutic and pharmacological effects of ginseng and ginsenosides in central nervous system. J Ginseng Res  2013,37(1),8-29","journal-title":"J Ginseng Res"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/10286020410001690172","volume":"7","author":"Xu B.B.","year":"2005","unstructured":"Xu B.B.; Liu C.Q.; Gao X.; Zhang W.Q.; Wang S.W.; Cao Y.L.; Possible mechanisms of the protection of ginsenoside Re against MPTP-induced apoptosis in substantia nigra neurons of Parkinson\u2019s disease mouse model. J Asian Nat Prod Res  2005,7(3),215-224","journal-title":"J Asian Nat Prod Res"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1517\/13543784.2010.482926","volume":"19","author":"Hardeland R.","year":"2010","unstructured":"Hardeland R.; Investigational melatonin receptor agonists. Expert Opin Investig Drugs  2010,19(6),747-764","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1600-079X.2006.00407.x","volume":"42","author":"Tan D.X.","year":"2007","unstructured":"Tan D.X.; Manchester L.C.; Terron M.P.; Flores L.J.; Reiter R.J.; One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res  2007,42(1),28-42","journal-title":"J Pineal Res"},{"key":"ref=131","author":"Natesan A.K.","year":"2001","unstructured":"Natesan A.K.; Thesis Molecular analysis of melatonin receptors in the chick central nervous system: Role for multiple receptor subtypes. Texas AandM University  2001","journal-title":"Texas AandM University"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"8638","DOI":"10.3390\/ijms14048638","volume":"14","author":"Carrillo-Vico A.","year":"2013","unstructured":"Carrillo-Vico A.; Lardone P.; \u00c1lvarez-S\u00e1nchez N.; Rodr\u00edguez-Rodr\u00edguez A.; Guerrero J.; Melatonin: Buffering the immune system. Int J Mol Sci  2013,14(4),8638-8683","journal-title":"Int J Mol Sci"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/nu9040367","volume":"9","author":"Meng X.","year":"2017","unstructured":"Meng X.; Li Y.; Li S.; Zhou Y.; Gan R.Y.; Xu D.P.; Li H.B.; Dietary sources and bioactivities of melatonin. Nutrients  2017,9(4),367","journal-title":"Nutrients"},{"key":"ref=134","author":"Arendt J.","unstructured":"Arendt J.; Aulinas A.; Physiology of the Pineal Gland and Melatonin, 2022, MDText.com, Inc., 2000."},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1600-079X.2012.01005.x","volume":"53","author":"Koh P.O.","year":"2012","unstructured":"Koh P.O.; Melatonin regulates the calcium-buffering proteins, parvalbumin and hippocalcin, in ischemic brain injury. J Pineal Res  2012,53(4),358-365","journal-title":"J Pineal Res"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"110761","DOI":"10.1016\/j.plantsci.2020.110761","volume":"303","author":"Li H.","year":"2021","unstructured":"Li H.; Guo Y.; Lan Z.; Zhang Z.; Ahammed G.J.; Chang J.; Zhang Y.; Wei C.; Zhang X.; Melatonin antagonizes ABA action to promote seed germination by regulating Ca efflux and HO accumulation. Plant Sci  2021,303,110761","journal-title":"Plant Sci"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.neuro.2016.09.002","volume":"57","author":"Pati\u00f1o P.","year":"2016","unstructured":"Pati\u00f1o P.; Parada E.; Farr\u00e9-Alins V.; Molz S.; Cacabelos R.; Marco-Contelles J.; L\u00f3pez M.G.; Tasca C.I.; Ramos E.; Romero A.; Egea J.; Melatonin protects against oxygen and glucose deprivation by decreasing extracellular glutamate and Nox-derived ROS in rat hippocampal slices. Neurotoxicology  2016,57,61-68","journal-title":"Neurotoxicology"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1600-079X.2007.00420.x","volume":"42","author":"Lee M.Y.","year":"2007","unstructured":"Lee M.Y.; Kuan Y.H.; Chen H.Y.; Chen T.Y.; Chen S.T.; Huang C.C.; Yang I.P.; Hsu Y.S.; Wu T.S.; Lee E.J.; Intravenous administration of melatonin reduces the intracerebral cellular inflammatory response following transient focal cerebral ischemia in rats. J Pineal Res  2007,42(3),297-309","journal-title":"J Pineal Res"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"5577541","DOI":"10.1155\/2021\/5577541","volume":"2021","author":"Jim\u00e9nez-Delgado A.","year":"2021","unstructured":"Jim\u00e9nez-Delgado A.; Ortiz G.G.; Delgado-Lara D.L.; Gonz\u00e1lez-Usigli H.A.; Gonz\u00e1lez-Ortiz L.J.; Cid-Hern\u00e1ndez M.; Cruz-Serrano J.A.; Pacheco-Mois\u00e9s F.P.; Effect of melatonin administration on mitochondrial activity and oxidative stress markers in patients with Parkinson\u2019s disease. Oxid Med Cell Longev  2021,2021(1),5577541","journal-title":"Oxid Med Cell Longev"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/j.1365-2621.2007.01558.x","volume":"43","author":"Allaith A.A.A.","year":"2008","unstructured":"Allaith A.A.A.; Antioxidant activity of Bahraini date palm ( Phoenix dactylifera L.) fruit of various cultivars. Int J Food Sci Technol  2008,43(6),1033-1040","journal-title":"Int J Food Sci Technol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.foodchem.2007.10.033","volume":"107","author":"Biglari F.","year":"2008","unstructured":"Biglari F.; AlKarkhi A.F.M.; Easa A.M.; Antioxidant activity and phenolic content of various date palm (Phoenix dactylifera) fruits from Iran. Food Chem  2008,107(4),1636-1641","journal-title":"Food Chem"},{"key":"ref=142","first-page":"483","volume":"7","author":"Rahmani A.H.","year":"2014","unstructured":"Rahmani A.H.; Aly S.M.; Ali H.; Babiker A.Y.; Srikar S.; Khan A.A.; Therapeutic effects of date fruits (Phoenix dactylifera) in the prevention of diseases via modulation of anti-inflammatory, anti-oxidant and anti-tumour activity. Int J Clin Exp Med  2014,7(3),483-491","journal-title":"Int J Clin Exp Med"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4103\/0975-9476.159073","volume":"6","author":"Essa M.M.","year":"2015","unstructured":"Essa M.M.; Braidy N.; Awlad-Thani K.; Vaishnav R.; Al-Asmi A.; Guillemin G.J.; Al-Adawi S.; Subash S.; Diet rich in date palm fruits improves memory, learning and reduces beta amyloid in transgenic mouse model of Alzheimer\u2032s disease. J Ayurveda Integr Med  2015,6(2),111-120","journal-title":"J Ayurveda Integr Med"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5897\/AJCPATH17.001","volume":"8","author":"Yusuf A.O.","year":"2017","unstructured":"Yusuf A.O.; Buraimoh A.A.; Agbon A.N.; Raji K.B.; Akpulu P.S.; Preliminary histological studies on the effect of aqueous fruit extract of Phoenix dactylifera L.(date palm) on lead acetate-induced cerebellar damages in Wistar rats. Afr J Cell Pathol  2017,8(1),1-8","journal-title":"Afr J Cell Pathol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1179\/1476830514Y.0000000134","volume":"18","author":"Subash S.","year":"2015","unstructured":"Subash S.; Essa M.M.; Al-Asmi A.; Al-Adawi S.; Vaishnav R.; Guillemin G.J.; Effect of dietary supplementation of dates in Alzheimer\u2019s disease APPsw\/2576 transgenic mice on oxidative stress and antioxidant status. Nutr Neurosci  2015,18(6),281-288","journal-title":"Nutr Neurosci"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10072-022-06493-y","volume":"44","author":"Rai S.N.","year":"2023","unstructured":"Rai S.N.; Singh P.; Varshney R.; Natural L-DOPA from Mucuna pruriens: A sustainable therapy for Parkinson\u2019s disease. Neurol Sci  2023,44(2),621-634","journal-title":"Neurol Sci"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2174\/1871527320666210118105418","volume":"20","author":"Thakur A.K.","year":"2021","unstructured":"Thakur A.K.; Rai G.; Mucuna pruriens in Parkinson\u2019s disease: Translational opportunities. CNS Neurol Disord Drug Targets  2021,20(5),416-429","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"114788","DOI":"10.1016\/j.jep.2021.114788","volume":"284","author":"Patel V.K.","year":"2022","unstructured":"Patel V.K.; Yadav S.K.; Singh S.; Mucuna pruriens enhances striatal dopamine release and motor coordination in MPTP-lesioned mice. J Ethnopharmacol  2022,284,114788","journal-title":"J Ethnopharmacol"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainresbull.2023.01.008","volume":"194","author":"Wang Y.","year":"2023","unstructured":"Wang Y.; Li S.; Chen L.; Ursolic acid attenuates neuroinflammation in MPTP mice by regulating microglial polarization via the PPAR\u03b3\/NF-\u03baB pathway. Brain Res Bull  2023,194,1-10","journal-title":"Brain Res Bull"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.cbi.2021.03.026","volume":"277","author":"Javed H.","year":"2021","unstructured":"Javed H.; Vaibhav K.; Khan M.M.; Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinson\u2019s disease mouse model. Chem Biol Interact  2021,277,91-100","journal-title":"Chem Biol Interact"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"8179","DOI":"10.3390\/ijms23158179","volume":"23","author":"Kim S.R.","year":"2022","unstructured":"Kim S.R.; Jeong H.Y.; Yang S.; Ursolic acid suppresses neuroinflammation in MPTP-induced Parkinson\u2019s disease mice via Nrf2\/HO-1 signaling. Int J Mol Sci  2022,23(15),8179","journal-title":"Int J Mol Sci"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3390\/antiox12030512","volume":"12","author":"Hwang C.J.","year":"2023","unstructured":"Hwang C.J.; Kim Y.E.; Son D.J.; Chlorogenic acid rescues mitochondrial dysfunction in Parkinson\u2019s disease models via PGC-1\u03b1 upregulation. Antioxidants  2023,12(3),512","journal-title":"Antioxidants"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"302","DOI":"10.4062\/biomolther.2020.154","volume":"29","author":"Lee J.E.","year":"2021","unstructured":"Lee J.E.; Song H.S.; Park J.H.; Chlorogenic acid ameliorates MPTP-induced neurotoxicity and motor deficits in mice by suppressing oxidative stress. Biomol Ther  2021,29(3),302-310","journal-title":"Biomol Ther"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"105385","DOI":"10.1016\/j.neuint.2022.105385","volume":"158","author":"Bollimpelli V.S.","year":"2022","unstructured":"Bollimpelli V.S.; Kumar P.; Kondapi A.K.; Neuroprotective effect of chlorogenic acid in MPTP-induced Parkinson\u2019s disease mice. Neurochem Int  2022,158,105385","journal-title":"Neurochem Int"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s12640-022-00503-9","volume":"40","author":"Singh M.","year":"2022","unstructured":"Singh M.; Murthy V.; Ramassamy C.; Standardized Withania somnifera extract inhibits apoptosis in Maneb-Paraquat-induced Parkinson\u2019s disease models. Neurotox Res  2022,40(3),714-727","journal-title":"Neurotox Res"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/j.1460-9568.2008.06024.x","volume":"27","author":"Kuboyama T.","year":"2020","unstructured":"Kuboyama T.; Tohda C.; Komatsu K.; Withanoside IV and its active metabolite, sominone, attenuate A\u03b2(25-35)-induced neurodegeneration. Eur J Neurosci  2020,27(3),647-658","journal-title":"Eur J Neurosci"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"154709","DOI":"10.1016\/j.phymed.2023.154709","volume":"112","author":"Sharma A.","year":"2023","unstructured":"Sharma A.; Kumar A.; Taliyan R.; Synergistic neuroprotection by Withania somnifera and coenzyme Q10 in a Parkinson\u2019s disease model: Role of mitochondrial biogenesis. Phytomedicine  2023,112,154709","journal-title":"Phytomedicine"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","volume":"71","author":"Beal M.F.","year":"2014","unstructured":"Beal M.F.; Oakes D.; Shoulson I.; Henchcliffe C.; Galpern W.R.; Haas R.; Juncos J.L.; Nutt J.G.; Voss T.S.; Ravina B.; Shults C.M.; Helles K.; Snively V.; Lew M.F.; Griebner B.; Watts A.; Gao S.; Pourcher E.; Bond L.; Kompoliti K.; Agarwal P.; Sia C.; Jog M.; Cole L.; Sultana M.; Kurlan R.; Richard I.; Deeley C.; Waters C.H.; Figueroa A.; Arkun A.; Brodsky M.; Ondo W.G.; Hunter C.B.; Jimenez-Shahed J.; Palao A.; Miyasaki J.M.; So J.; Tetrud J.; Reys L.; Smith K.; Singer C.; Blenke A.; Russell D.S.; Cotto C.; Friedman J.H.; Lannon M.; Zhang L.; Drasby E.; Kumar R.; Subramanian T.; Ford D.S.; Grimes D.A.; Cote D.; Conway J.; Siderowf A.D.; Evatt M.L.; Sommerfeld B.; Lieberman A.N.; Okun M.S.; Rodriguez R.L.; Merritt S.; Swartz C.L.; Martin W.R.W.; King P.; Stover N.; Guthrie S.; Watts R.L.; Ahmed A.; Fernandez H.H.; Winters A.; Mari Z.; Dawson T.M.; Dunlop B.; Feigin A.S.; Shannon B.; Nirenberg M.J.; Ogg M.; Ellias S.A.; Thomas C.A.; Frei K.; Bodis-Wollner I.; Glazman S.; Mayer T.; Hauser R.A.; Pahwa R.; Langhammer A.; Ranawaya R.; Derwent L.; Sethi K.D.; Farrow B.; Prakash R.; Litvan I.; Robinson A.; Sahay A.; Gartner M.; Hinson V.K.; Markind S.; Pelikan M.; Perlmutter J.S.; Hartlein J.; Molho E.; Evans S.; Adler C.H.; Duffy A.; Lind M.; Elmer L.; Davis K.; Spears J.; Wilson S.; Leehey M.A.; Hermanowicz N.; Niswonger S.; Shill H.A.; Obradov S.; Rajput A.; Cowper M.; Lessig S.; Song D.; Fontaine D.; Zadikoff C.; Williams K.; Blindauer K.A.; Bergholte J.; Propsom C.S.; Stacy M.A.; Field J.; Mihaila D.; Chilton M.; Uc E.Y.; Sieren J.; Simon D.K.; Kraics L.; Silver A.; Boyd J.T.; Hamill R.W.; Ingvoldstad C.; Young J.; Thomas K.; Kostyk S.K.; Wojcieszek J.; Pfeiffer R.F.; Panisset M.; Beland M.; Reich S.G.; Cines M.; Zappala N.; Rivest J.; Zweig R.; Lumina L.P.; Hilliard C.L.; Grill S.; Kellermann M.; Tuite P.; Rolandelli S.; Kang U.J.; Young J.; Rao J.; Cook M.M.; Severt L.; Boyar K.; A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: No evidence of benefit. JAMA Neurol  2014,71(5),543-552","journal-title":"JAMA Neurol"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1001\/jama.2015.120","volume":"313","author":"Kieburtz K.","year":"2015","unstructured":"Kieburtz K.; Tilley B.C.; Elm J.J.; Babcock D.; Hauser R.; Ross G.W.; Augustine A.H.; Augustine E.U.; Aminoff M.J.; Bodis-Wollner I.G.; Boyd J.; Cambi F.; Chou K.; Christine C.W.; Cines M.; Dahodwala N.; Derwent L.; Dewey R.B.; Hawthorne K.; Houghton D.J.; Kamp C.; Leehey M.; Lew M.F.; Liang G.S.L.; Luo S.T.; Mari Z.; Morgan J.C.; Parashos S.; P\u00e9rez A.; Petrovitch H.; Rajan S.; Reichwein S.; Roth J.T.; Schneider J.S.; Shannon K.M.; Simon D.K.; Simuni T.; Singer C.; Sudarsky L.; Tanner C.M.; Umeh C.C.; Williams K.; Wills A.M.; Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: A randomized clinical trial. JAMA  2015,313(6),584-593","journal-title":"JAMA"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","volume":"77","author":"Mullin S.","year":"2020","unstructured":"Mullin S.; Smith L.; Lee K.; D\u2019Souza G.; Woodgate P.; Elflein J.; H\u00e4llqvist J.; Toffoli M.; Streeter A.; Hosking J.; Heywood W.E.; Khengar R.; Campbell P.; Hehir J.; Cable S.; Mills K.; Zetterberg H.; Limousin P.; Libri V.; Foltynie T.; Schapira A.H.V.; Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: A nonrandomized, noncontrolled trial. JAMA Neurol  2020,77(4),427-434","journal-title":"JAMA Neurol"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.neuron.2010.04.034","volume":"66","author":"Dawson T.M.","year":"2010","unstructured":"Dawson T.M.; Ko H.S.; Dawson V.L.; Genetic animal models of Parkinson\u2019s disease. Neuron  2010,66(5),646-661","journal-title":"Neuron"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/ana.24011","volume":"74","author":"Olanow C.W.","year":"2013","unstructured":"Olanow C.W.; Schapira A.H.V.; Therapeutic prospects for Parkinson disease. Ann Neurol  2013,74(3),337-347","journal-title":"Ann Neurol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.parkreldis.2015.04.029","volume":"21","author":"Puschmann A.","year":"2015","unstructured":"Puschmann A.; Brighina L.; Markopoulou K.; Aasly J.; Chung S.J.; Frigerio R.; Hadjigeorgiou G.; K\u00f5ks S.; Kr\u00fcger R.; Siuda J.; Wider C.; Zesiewicz T.A.; Maraganore D.M.; Clinically meaningful parameters of progression and long-term outcome of Parkinson disease: An international consensus statement. Parkinsonism Relat Disord  2015,21(7),675-682","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","volume":"2","author":"Pardridge W.M.","year":"2005","unstructured":"Pardridge W.M.; The blood-brain barrier: Bottleneck in brain drug development. NeuroRx  2005,2(1),3-14","journal-title":"NeuroRx"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3390\/pharmaceutics14020224","volume":"14","author":"Ayub A.","year":"2022","unstructured":"Ayub A.; Wettig S.; An overview of nanotechnologies for drug delivery to the brain. Pharmaceutics  2022,14(2),224","journal-title":"Pharmaceutics"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"112117","DOI":"10.1016\/j.biopha.2021.112117","volume":"143","author":"Nguyen T.T.","year":"2021","unstructured":"Nguyen T.T.; Dung Nguyen T.T.; Vo T.K.; Tran N.M.A.; Nguyen M.K.; Van Vo T.; Van Vo G.; Nanotechnology-based drug delivery for central nervous system disorders. Biomed Pharmacother  2021,143,112117","journal-title":"Biomed Pharmacother"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S0006-8993(00)03269-8","volume":"892","author":"Dawson D.A.","year":"2001","unstructured":"Dawson D.A.; Wadsworth G.; Palmer A.M.; A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke. Brain Res  2001,892(2),344-350","journal-title":"Brain Res"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"101665","DOI":"10.1016\/j.redox.2020.101665","volume":"36","author":"Kalyanaraman B.","year":"2020","unstructured":"Kalyanaraman B.; Teaching the basics of repurposing mitochondria-targeted drugs: From Parkinson\u2019s disease to cancer and back to Parkinson\u2019s disease. Redox Biol  2020,36,101665","journal-title":"Redox Biol"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"S205","DOI":"10.3233\/JAD-2010-091459","volume":"20","author":"Prediger R.D.S.","year":"2010","unstructured":"Prediger R.D.S.; Effects of caffeine in Parkinson\u2019s disease: From neuroprotection to the management of motor and non-motor symptoms. J Alzheimers Dis  2010,20(s1),S205-S220","journal-title":"J Alzheimers Dis"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"107247","DOI":"10.1016\/j.phrs.2024.107247","volume":"205","author":"Gri\u00f1\u00e1n-Ferr\u00e9 C.","year":"2024","unstructured":"Gri\u00f1\u00e1n-Ferr\u00e9 C.; Bellver-Sanchis A.; Guerrero A.; Pall\u00e0s M.; Advancing personalized medicine in neurodegenerative diseases: The role of epigenetics and pharmacoepigenomics in pharmacotherapy. Pharmacol Res  2024,205,107247","journal-title":"Pharmacol Res"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.3390\/jpm12091485","volume":"12","author":"Pandey S.","year":"2022","unstructured":"Pandey S.; Jir\u00e1sko M.; Lochman J.; Chv\u00e1tal A.; Chottova D.M.; Ku\u010dera R.; iPSCs in neurodegenerative disorders: A unique platform for clinical research and personalized medicine. J Pers Med  2022,12(9),1485","journal-title":"J Pers Med"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3390\/genes11070747","volume":"11","author":"Strianese O.","year":"2020","unstructured":"Strianese O.; Rizzo F.; Ciccarelli M.; Galasso G.; D\u2019Agostino Y.; Salvati A.; Del Giudice C.; Tesorio P.; Rusciano M.R.; Precision and personalized medicine: How genomic approach improves the management of cardiovascular and neurodegenerative disease. Genes  2020,11(7),747","journal-title":"Genes"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3390\/biomedicines10020371","volume":"10","author":"Gouda N.A.","year":"2022","unstructured":"Gouda N.A.; Elkamhawy A.; Cho J.; Emerging therapeutic strategies for Parkinson\u2019s disease and future prospects: A 2021 update. Biomedicines  2022,10(2),371","journal-title":"Biomedicines"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/mds.26428","volume":"31","author":"Valera  E.","year":"2016","unstructured":"Valera E.; Masliah E.;  Combination therapies: The next logical Step for the treatment of synucleinopathies? Mov Disord  2016,31(2),225","journal-title":"Mov Disord"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3233\/JAD-161068","volume":"56","author":"Matsunaga S.","year":"2017","unstructured":"Matsunaga S.; Kishi T.; Iwata N.; Combination therapy with Zonisamide and Antiparkinson drugs for Parkinson\u2019s disease: A meta-analysis. J Alzheimers Dis  2017,56(4),1229","journal-title":"J Alzheimers Dis"}],"container-title":["Current Alzheimer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115672050368080250529075006","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/243976\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115672050368080250529075006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T15:15:54Z","timestamp":1768230954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/243976\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":175,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115672050368080250529075006","relation":{},"ISSN":["1567-2050"],"issn-type":[{"value":"1567-2050","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-12-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}